AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 0 cutMore adding
Market overview
Fundamentals Aug 17- 52-wk high
- $25.49
- 52-wk low
- $10.63
- Mkt cap
- $1.17B
- Fwd P/E
- 30.7x
- Beta
- 1.57
- P/S
- 1.6x
- P/B
- 1.5x
- Profit margin
- -10.4%
- Op margin
- +5.4%
- ROE
- -9.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about AVNS filings
Are insiders buying or selling Avanos Medical Inc (AVNS) stock?
Neither. Avanos Medical Inc (AVNS) insiders filed no open-market purchases or sales in the 90 days to Oct 5, 2026, according to SEC Form 4 filings.
Which members of Congress have traded AVNS recently?
None. No member of Congress disclosed a AVNS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this AVNS smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (2)
- MI
Millennium
$37.7M
added
- JC
JPMorgan Chase
$24.0M
added
How top traders are positioned
No tracked top-trader positions in AVNS right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No earnings history.
What the street expects next
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -10.4%
- Forward P/E
- 30.67
- Market cap
- $1.2B
Valuation
- P/S1.64
- P/B1.50
Quality
- Operating margin5.4%
- ROE-9.2%
- ROA0.9%
Growth
- Beta1.57
Technicals
Price structure
Market data unavailable.